AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12576934
Drug: Oral doxifluridine
RxNorm normalized name: Trifluridine
DrugBank: Trifluridine (DB00432)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral doxifluridine 1,000 mg/m²/d plus leucovorin 30 mg/d on days 1 to 7 and 15 to 21 of each cycle (group A)
Trial: 12576934
Drug: Intravenous 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5‐fluorouracil 400 mg/m²/d plus leucovorin 20 mg/m²/d on days 1‐5 of each cycle (group B)
Trial: 10220204
Drug: 1600 i.u.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 i.u. daily oral alpha-tocopherol for 8 weeks
Trial: 1340687
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms BIM (continuous s.c. infusion for 24 hours)
Trial: 1340687
Drug: 1500 micrograms/24h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 micrograms/24h BIM (as 500 micrograms x 3 s.c. injections, 750 micrograms x 2 s.c. injections, and continuous s.c. infusion)
Trial: 1340687
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg IM of a long acting formulation of BIM
Trial: 31279613
Drug: Telephone-administered psycho-education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered psycho-education with behavioral activation intervention (TBA)
Trial: 18028017
Drug: Anastrozole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (5 years treatment)
Trial: 9933696
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia (TEA) with 2% lidocaine (15-20 ml), midazolam (5-10 mg), and fentanyl (<250 microg)
Trial: 2305976
Drug: CIT (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIT (Conventional Intermittent 'Top-Up' Injections)
Trial: 25747263
Drug: Stereotactic body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic body radiotherapy (SBRT) with a dose prescription of 35 Gy in five fractions
Trial: 8853765
Drug: Mesalazine (Asacol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine (Asacol 1.6 g daily)
Trial: 8853765
Drug: Olsalazine (Dipentum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olsalazine (Dipentum 1.0 g daily)
Trial: 29195028
Drug: Mast cell
RxNorm normalized name: Mast cell protease 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mast cell stabilizer (1 mg ketotifen twice daily for three months)
Trial: 29195028
Drug: Varicocelectomy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Varicocelectomy followed by mast cell stabilizer (1 mg ketotifen twice daily for three months)
Trial: 27067196
Drug: Dihydroartemisinin-piperaquine (DP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroartemisinin-piperaquine (DP), administered monthly from 6 to 24 months of age.
Trial: 22305890
Drug: Atorvastatin in
RxNorm normalized name: Product containing atorvastatin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin in combination with carboplatin
Trial: 22305890
Drug: Atorvastatin and
RxNorm normalized name: atorvastatin and ezetimibe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and carboplatin
Trial: 20561549
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) use group
Trial: 15778928
Drug: Basal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal glucose concentration (G (b)) assigned the value of fasting plasma glucose concentration (G (fast))
Trial: 15778928
Drug: Basal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal glucose concentration (G (b)) assigned the value of plasma glucose concentration 180 minutes after the start of the IVGTT (G (180))
Trial: 12835077
Drug: Novel drug
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel drug delivery system with coarse dispersion (average particle size 1-150 microm)
Trial: 11391543
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily for 3 years
Trial: 2960494
Drug: Etodolac 200
RxNorm normalized name: etodolac 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 200 mg twice daily
Trial: 26865083
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% continuous wound infiltration (8 ml/h)
Trial: 26865083
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received intraoperative low-dose ketamine, acetaminophen, NSAIDs, nefopam, and morphine PCA
Trial: 26806502
Drug: Spironolactone (25‐50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25‐50 mg)
Trial: 22985207
Drug: 1 μg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg·kg(‐1) intranasally (group N)
Trial: 22985207
Drug: 1 μg·kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg·kg(‐1) buccally (group B)
Trial: 17011500
Drug: MK-0557, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0557, 1 mg/day
Trial: 8070826
Drug: Lidocaine prophylaxis
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine prophylaxis (1.5 mg/kg bolus followed by 2 mg/min infusion)
Trial: 31647464
Drug: Topical 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5-fluorouracil (chemoprevention of KC)
Trial: 29482983
Drug: Switch strategy
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch strategy (2 years of tamoxifen followed by 3 years of aromatase inhibitors)
Trial: 29482983
Drug: Upfront treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront treatment (5 years of aromatase inhibitors)
Trial: 29482983
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg per day for 5 years)
Trial: 29482983
Drug: Exemestane (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exemestane (25 mg per day for 5 years)
Trial: 29482983
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg per day for 5 years)
Trial: 29482983
Drug: Upfront treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront treatment
Trial: 24789736
Drug: Problem Solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem Solving Therapy for Primary Care (PST-PC)
Trial: 20698956
Drug: Stroke volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke volume guided fluid therapy combined with dopexamine (0.5 mcg/kg/min) (SV & DPX group)
Trial: 20698956
Drug: Stroke volume
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroke volume guided fluid therapy (SV group)
Trial: 20698956
Drug: Central venous
RxNorm normalized name: ACCUGUIDE CENTRAL VENOUS CATHETER KIT C1409AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Central venous pressure guided fluid therapy (CVP group)
Trial: 16055957
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/d) and calcium carbonate (500 mg/d)
Trial: 16055957
Drug: Estradiol implant
RxNorm normalized name: Oestradiol Implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol implant (25 mg, replaced every 6 mo)
Trial: 16055957
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (500 mg/d) only (Control for alendronate group)
Trial: 9973655
Drug: Ebselen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ebselen (150 mg b.i.d. for 2 weeks)
Trial: 550621
Drug: diisopropylamine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diisopropylamine (3 times 200 mg a day)
Trial: 550621
Drug: reserpine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reserpine (3 times 0.25 mg a day)
Trial: 11991216
Drug: perindopril 4
RxNorm normalized name: perindopril 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: perindopril 4 mg once daily (n = 42)
Trial: 11991216
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg once daily (n = 43)
Trial: 9655533
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 10 mg/kg twice daily for 5 days
Trial: 9655533
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 10 mg/kg twice daily for 10 days
Trial: 8732151
Drug: Bushenhuoxue Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushenhuoxue Tablet (BSHX)
Trial: 27797997
Drug: Electronic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic medication management (eMM) system implemented in paediatric wards, details on dosage and duration not specified.
Trial: 27797997
Drug: Modified electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified electronic medication management (eMM) system implemented in the second paediatric hospital, details on dosage and duration not specified.
Trial: 25428337
Drug: Adjunctive Buchang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive Buchang Naoxintong Capsule (NXT)
Trial: 25428337
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (clopidogrel 75 g)
Trial: 20121658
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (22 or 44 mcg three times weekly)
Trial: 20121658
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (44 mcg)
Trial: 20121658
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (22 mcg)
Trial: 17540662
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) implantation
Trial: 12598816
Drug: Acetyl-L-carnitine (Alcar)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (Alcar)
Trial: 1992304
Drug: Solution A
RxNorm normalized name: I.V. SOLUTION ADDITIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution A (rice-syrup solids)
Trial: 1992304
Drug: Solution C
RxNorm normalized name: Salt solution combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution C (glucose-based solution, control)
Trial: 6340973
Drug: Glucametacin (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucametacin (420 mg daily for 20 days)
Trial: 6340973
Drug: Ketoprofen (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen (300 mg daily for 20 days)
Trial: 28060040
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cysticidal therapy mentioned)
Trial: 23369024
Drug: Loxoprofen (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxoprofen (180 mg/day)
Trial: 19587472
Drug: Ibuprofen 500
RxNorm normalized name: ibuprofen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 500 mg, three times a day for nine days
Trial: 19587472
Drug: Mesalamine 400
RxNorm normalized name: mesalamine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalamine 400 mg, three times a day for nine days
Trial: 11772973
Drug: Terlipressin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (3 mg)
Trial: 11772973
Drug: Albumin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (8 g/l of removed ascites)
Trial: 9882082
Drug: Dexketoprofen trometamol
RxNorm normalized name: Dexketoprofen trometamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen trometamol 12.5 mg
Trial: 8071037
Drug: iopromide (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopromide (370 mg I/mL)
Trial: 8071037
Drug: iohexol (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol (350 mg I/mL)
Trial: 241357
Drug: LF 17-895
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF 17-895 (10 mg oral dose)
Trial: 241357
Drug: LF 17-895
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF 17-895 (4 mg intravenous dose)
Trial: 241357
Drug: Pindolol (comparison
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (comparison drug)
Trial: 30575345
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Group 2)
Trial: 27626368
Drug: Nonsurgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical treatment (Group 1)
Trial: 26044218
Drug: Nasotracheal suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasotracheal suction mechanical ventilation treatment (test group)
Trial: 26044218
Drug: Noninvasive positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive positive pressure ventilation (CPAP) treatment (control group)
Trial: 17187274
Drug: A +
RxNorm normalized name: Vital E- A + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A + HA group (arthroscopic knee joint lavage followed by 10 ml of 0.5% sodium hyaluronate)
Trial: 15006059
Drug: Transurethral resection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transurethral resection of the prostate (TURP) plus sequential laparoscopic bladder diverticulectomy
Trial: 11557928
Drug: Noncontact normothermic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontact normothermic wound therapy (3 treatments daily, dressing warmed to 38 degrees C for 1 hour)
Trial: 11557928
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (moisture retentive dressings providing absorption as needed)
Trial: 2091073
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Nitrendipine + Chlorthalidone)
Trial: 31730174
Drug: Spironolactone-pioglitazone-metformin (SPIOMET)
RxNorm normalized name: metformin / pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone-pioglitazone-metformin (SPIOMET) for 1 year
Trial: 31730174
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) for 1 year
Trial: 24135894
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of avocado soybean unsaponifiables (ASU) for 3 months
Trial: 10923219
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart (0.15 IU/kg body weight)
Trial: 10923219
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (0.15 IU/kg body weight)
Trial: 10923219
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart and Human insulin
Trial: 1343612
Drug: Intravenous sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sedation with 30 mg of pentazocine and 5 mg of diazepam
Trial: 1343612
Drug: Hematoma block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematoma block with 20 cc of 1.5% Xylocaine
Trial: 30055335
Drug: Intensive prolonged
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive prolonged exposure therapy (exact details of dosage and duration not specified, but treatment is administered daily over a 3-week period)
Trial: 2698946
Drug: Nifedipine AR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Adalat AR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine AR (20 mg twice a day)
Trial: 2698946
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet twice a day)
Trial: 31381231
Drug: Subcutaneous Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous Methotrexate (MTX)
Trial: 28439994
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg once daily, adjustable to 100 or 25 mg as needed)
Trial: 17275886
Drug: Dalteparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (5000 U, subcutaneous injections, once daily until ulcer healing or for a maximum of six months)
Trial: 15457352
Drug: Talc slurry
RxNorm normalized name: Talc
DrugBank: Talc (DB09511)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Talc slurry (TS) 4 g
Trial: 11037053
Drug: IL-2 presurgical
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 presurgical immunotherapy (12 million IU/day for 3 days subcutaneously)
Trial: 11037053
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without IL-2 presurgical immunotherapy)
Trial: 9272407
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch renewed on a new skin location
Trial: 9272407
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch renewed on the previous application site
Trial: 8386652
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: NCI regimen with vinblastine, etoposide, bleomycin and double dose cisplatin (PVeBV) 3 or 4 cycles Q3W
Trial: 8386652
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: modified PVeBV protocol (bleomycin in continuous infusion) Q4W than a cycle of high-dose E + cyclophosphamide + P2 (PEC) and autologous bone marrow transplantation (ABMT)
Trial: 20850847
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin (100 pmol/L)
Trial: 20850847
Drug: Medium-dose insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium-dose insulin (400 pmol/L)
Trial: 20850847
Drug: Hyperglycemia (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (12 mmol/L)
Trial: 20850847
Drug: Lipopolysaccharide administration
RxNorm normalized name: sulfated mucopolysaccharides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipopolysaccharide administration (to mimic sepsis)
Trial: 20850847
Drug: Euglycemia (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (5 mmol/L)
Trial: 14592280
Drug: nCPAP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nCPAP plus modafinil (200 mg/day for week 1; 400 mg/day for weeks 2-4)
Trial: 23230283
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h for 7 days
Trial: 23230283
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN) 0.6 mg/h (acute administration)
Trial: 17028482
Drug: Amlodipine besylate/benazepril
RxNorm normalized name: amlodipine besylate/benazepril 5 mg-10 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/benazepril HCl (5/20 mg/d force‐titrated to 5/40 mg/d)
Trial: 17028482
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate monotherapy (5 mg/d force‐titrated to 10 mg/d)
Trial: 7695323
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil oral suspension with food
Trial: 7695323
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil oral suspension under fasting conditions
Trial: 2695815
Drug: 100 I.U.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 I.U. of salmon calcitonin (sCT) nasal spray daily (n = 20)
Trial: 2695815
Drug: 100 I.U.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 I.U. of sCT by subcutaneous injection every second day (n = 10)
Trial: 2695815
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium supplement, 1 g per day (control group, n = 10)
Trial: 2695815
Drug: Calcitonin groups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitonin groups (sCT nasal spray and subcutaneous injection)
Trial: 334475
Drug: Flurbiprofen (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (150 mg to 300 mg daily)
Trial: 334475
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg to 150 mg daily)